In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a COVID-19 graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)